...
首页> 外文期刊>Journal of Cytology >Immunocytochemistry using Liquid-based Cytology: A Tool in Hormone Receptor Analysis of Breast Cancer
【24h】

Immunocytochemistry using Liquid-based Cytology: A Tool in Hormone Receptor Analysis of Breast Cancer

机译:使用基于液体的细胞学的免疫细胞化学:一种乳腺癌激素受体分析的工具

获取原文
获取原文并翻译 | 示例
           

摘要

Context: Efficacy of immunocytochemistry (ICC) in determining molecular biomarkers like estrogen receptor (ER), progesterone receptors (PRs), and human epidermal growth factor receptor-2 (HER2). Aims: To evaluate biomarkers using ICC in breast cancer as per American Society of Clinical Oncology/College of American Pathology (ASCO/CAP) guidelines. Settings and Design: The study was conducted over a period of 2 years from September 2012 to August 2014 and is the first such study in eastern India. Materials and Methods: Fine needle aspiration cytology (FNAC) was done for suspected cases of breast cancers and slides were prepared using ThinPrep (TP) technology of liquid-based cytology (LBC) for ICC and corresponding biopsy specimens were processed as formalin fixed paraffin embedded (FFPE) sections for comparison. Both the LBC slides and tissue sections were subjected to immunostaining for ER, PR, and HER2. ICC was evaluated by Allred Scoring and IHC by Quick Scoring. Statistical Analysis Used: Statistical analysis done by Wilconxon Signed rank test on the SPSS program, Chicago, Illinois, USA. The results of ICC and IHC were compared by evaluation of sensitivity, specificity, kappa-value (k-value), positive predictive value (PPV), and negative predictive value (NPV). Results: The comparison of ICC with immunohistochemistry (IHC), ER, and PR showed very good correspondence rate, sensitivity, specificity, NPV, PPV, and agreement with k-value; whereas for HER2 the results were only good. Conclusion: ICC using LBC can be a useful tool in assessing biomarkers in advanced cases of breast cancer where surgery is not possible or cases where ASCO/CAP guidelines for management are not followed.
机译:背景:免疫细胞化学(ICC)在测定雌激素受体(ER),孕酮受体(PRS)和人表皮生长因子受体-2(HER2)等分子生物标志物中的疗效。目的:根据美国临床肿瘤学会/美国病理学学院(ASCO / CAP)指南,评估使用ICC在乳腺癌中使用ICC的生物标志物。设置和设计:2012年9月至2014年8月的2年来进行该研究,是印度东部的第一个研究。材料和方法:细针抽吸细胞学(FNAC)用于疑似乳腺癌病例,并使用液体基细胞学(LBC)制备液体基础细胞学(LBC)的载玻片,并将相应的活组织检查标本作为福尔马林固定的石蜡加工(FFPE)部分进行比较。将LBC载玻片和组织切片均对ER,PR和HER2进行免疫染色。通过快速评分,由Alrred得分和IHC评估ICC。使用的统计分析:Wilconxon签署的SPSS计划,芝加哥,USA的统计分析。通过评估敏感性,特异性,κ值(K值),阳性预测值(PPV)和负预测值(NPV)来比较ICC和IHC的结果。结果:ICC与免疫组织化学(IHC),ER和PR的比较显示出非常良好的对应率,敏感性,特异性,NPV,PPV和K值的协议;而对于HER2,结果才擅长。结论:ICC使用LBC可以是评估乳腺癌晚期患者生物标志物的有用工具,其中手术是不可能的,或者没有遵循管理层的ASCO / CAP指南的情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号